HomeCompareBLMIF vs PFE

BLMIF vs PFE: Dividend Comparison 2026

BLMIF yields 4.66% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BLMIF wins by $4136.34M in total portfolio value
10 years
BLMIF
BLMIF
● Live price
4.66%
Share price
$23.83
Annual div
$1.11
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4136.39M
Annual income
$3,972,556,630.06
Full BLMIF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — BLMIF vs PFE

📍 BLMIF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBLMIFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BLMIF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BLMIF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BLMIF
Annual income on $10K today (after 15% tax)
$395.93/yr
After 10yr DRIP, annual income (after tax)
$3,376,673,135.55/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, BLMIF beats the other by $3,376,650,815.65/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BLMIF + PFE for your $10,000?

BLMIF: 50%PFE: 50%
100% PFE50/50100% BLMIF
Portfolio after 10yr
$2068.22M
Annual income
$1,986,291,444.39/yr
Blended yield
96.04%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

BLMIF
No analyst data
Altman Z
0.4
Piotroski
6/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BLMIF buys
0
PFE buys
0
No recent congressional trades found for BLMIF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBLMIFPFE
Forward yield4.66%6.13%
Annual dividend / share$1.11$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%13.2%
Portfolio after 10y$4136.39M$49.6K
Annual income after 10y$3,972,556,630.06$26,258.71
Total dividends collected$4124.83M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BLMIF vs PFE ($10,000, DRIP)

YearBLMIF PortfolioBLMIF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$11,632$931.60$9,153$693.39+$2.5KBLMIF
2$14,471$2,025.42$8,593$849.25+$5.9KBLMIF
3$20,194$4,710.06$8,336$1,066.78+$11.9KBLMIF
4$33,893$12,285.59$8,437$1,384.80+$25.5KBLMIF
5$74,808$38,541.60$9,013$1,875.40+$65.8KBLMIF
6$239,047$159,003.17$10,306$2,680.72+$228.7KBLMIF
7$1,205,489$949,708.03$12,820$4,101.38+$1.19MBLMIF
8$10,241,780$8,951,907.53$17,673$6,826.70+$10.22MBLMIF
9$153,117,632$142,158,926.62$27,543$12,591.86+$153.09MBLMIF
10$4,136,392,496$3,972,556,630.06$49,560$26,258.71+$4136.34MBLMIF

BLMIF vs PFE: Complete Analysis 2026

BLMIFStock

Bank Leumi le-Israel B.M., together with its subsidiaries, provides banking and financial services in Israel, the United States, the United Kingdom, and internationally. It operates through Households, Private Banking, Micro Businesses, Small Businesses, Mid-market, Corporations, Institutional Entities, and Financial Management segments. It provides housing loans, collateral loans, and loans to purchasing groups, including mortgage planning, accompanying the customer through the mortgage process, and recycling existing loans; and working capital, acquisitions, and term loans, as well as credit lines; financial support to Israeli high-tech companies; equipment lease financing; credit cards; and online banking services, as well as wealth and cash management services. The company also offers international trade financing, loan syndications and participations, foreign currency time deposits, and dealing room services. In addition, it provides provident funds, mutual funds, study funds, pension funds, and insurance products; invests in marketable securities, market-making activity involving securities and derivatives, repurchase and lending transactions involving securities, short selling of securities, and securities' underwriting services; engages in asset and liability management activities; and provides trust and custodial services for banks. Further, the company engages in the activities, such as advisory services, sale and management of loan portfolios, and development of financial products. Additionally, it provides banking services to private customers and small businesses, largest and multinational corporations, and middle-market companies, as well as financial services to institutional customers and foreign banks. The company operates approximately 250 branches. Bank Leumi le- Israel B.M. was founded in 1902 and is headquartered in Tel Aviv-Yafo, Israel.

Full BLMIF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this BLMIF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BLMIF vs SCHDBLMIF vs JEPIBLMIF vs OBLMIF vs KOBLMIF vs MAINBLMIF vs JNJBLMIF vs MRKBLMIF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.